James P. Allison

James P. Allison is Regental Professor and Chair of the Department of Immunology at The University of Texas MD Anderson Cancer Center, where he also holds the Olga Keith Wiess Distinguished University Chair for Cancer Research. He serves as Director of the James P. Allison Institute, Executive Director of the Immunotherapy Platform, and Director of the Parker Institute for Cancer Immunotherapy. His pioneering work in T cell biology and immune checkpoint blockade has revolutionized cancer treatment.

Research Interests:
Dr. Allison’s research centers on the regulation of T cell responses and the development of cancer immunotherapies. He is best known for discovering that blocking the CTLA-4 protein enhances T cell activation and enables tumor rejection. His work laid the foundation for immune checkpoint inhibitors, a transformative class of cancer drugs. Current research focuses on improving existing therapies, identifying new immune targets, and understanding mechanisms of response and resistance across cancers. His lab integrates basic immunology with translational and clinical research to accelerate therapeutic breakthroughs.

Scientific Trends in Publications:
His recent publications reflect a sustained focus on immune checkpoint biology, mechanisms of resistance, co-stimulatory pathways, and next-generation immunotherapies. The work spans from fundamental T cell signaling to clinical translation, emphasizing biomarker discovery, combination strategies, and personalized treatment approaches. There is a clear trend toward interdisciplinary collaboration, reverse translational research, and leveraging data science to inform laboratory studies.

Scientific Awards and Honors:

• Nobel Prize in Physiology or Medicine (2018)
• Lasker-DeBakey Clinical Medical Research Award (2015)
• Member, National Academy of Sciences
• Member, National Academy of Medicine
• Kovalenko Medal, National Academy of Sciences
• TIME 100 Most Influential People
• William B. Coley Award
• Szent-Györgyi Prize for Progress in Cancer Research
• Crafoord Prize in Polyarthritis
• American Association of Immunologists Lifetime Achievement Award

Advising, Grants, and Leadership:
Dr. Allison has mentored numerous graduate students, postdoctoral fellows, and early-career scientists across institutions including MD Anderson, UC Berkeley, and Memorial Sloan Kettering. He leads large collaborative initiatives such as the Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team and the Parker Institute for Cancer Immunotherapy. His research has been supported by major grants from the National Institutes of Health (NIH), National Cancer Institute (NCI), Cancer Prevention & Research Institute of Texas (CPRIT), Howard Hughes Medical Institute (HHMI), Cancer Research Institute, Prostate Cancer Foundation, and Stand Up to Cancer.

Labs and Research Teams:
Dr. Allison leads the Allison Lab at MD Anderson and co-leads the Immunotherapy Platform with Dr. Padmanee Sharma. The James P. Allison Institute, launched in 2022, serves as a multidisciplinary hub for immunobiology research, integrating discovery, translational, and clinical science. The institute fosters dynamic, project-focused teams across disciplines and collaborates with pharmaceutical partners to accelerate drug development. It is supported by MD Anderson’s Therapeutics Discovery division, core research platforms, and data science infrastructure.